MOL #65839
INTRODUCTION Lapatinib (Fig. 1) , the first oral dual tyrosine kinase inhibitor of ErbB-1 and ErbB-2, was approved by the FDA in 2007. As a targeted therapy that inhibits the tyrosine kinase domains on ErbB-1 and ErbB-2, it inhibits downstream cell proliferation and induces apoptosis by the ERK1/2 and PI3K/Akt pathways, respectively (Rusnak et al., 2001; Xia et al., 2002) . Lapatinib is usually indicated for co-administration with capecitabine in those patients having the subtype of advanced metastatic breast cancer in which there is ErbB-2 over-expression and resistance to standard therapy such as anthracyclines (e.g. doxorubicin) and taxane (Medina and Goodin, 2008) . Both in vitro and in vivo data further demonstrated lapatinib's effectiveness even in cases resistant to trastuzumab, the first therapeutic monoclonal antibody directed against ErbB-2 (Ryan et al., 2008) . The potential of lapatinib's efficacy in metastatic breast cancer has also been demonstrated in various trials (Nelson and Dolder, 2007) . Hence, lapatinib presents itself as a promising alternative and orally available drug for the disease.
However, a black boxed warning for lapatinib-related hepatotoxicity was released following post-marketing surveillance and clinical trial reports on elevated liver enzymes and rare cases of liver-related deaths (Gomez et al., 2008) . Fatalities stemming from hepatotoxicity associated with its clinical use were also reported recently (European Medicines Agency, 2008) . Since the hepatotoxicity of lapatinib has occurred in small numbers of patients and develops several days to months after commencement of therapy, its toxicity appears to be idiosyncratic in nature. To date, the mechanism by which lapatinib causes hepatotoxity is unknown.
Lapatinib is extensively metabolized by cytochrome P450 enzymes (CYP450), in particular CYP3A4/5 and to a lesser extent, CYP2C8 (European Medicines Agency, 2008 ). Our in-house studies demonstrated that lapatinib is metabolized to form O-and Ndealkylated metabolites, M1 and M2, respectively (Fig. 1) . Specifically, the structure of O-dealkylated lapatinib has the potential to generate a reactive quinoneimine similar to the model hepatotoxin acetaminophen (Hinson JA et al., 1981; Dahlin DC et al., 1984) .
Quinoneimines are electrophilic and have the propensity to react with nucleophilic groups of cellular proteins leading to toxicities. In fact, such bioactivation of drugs to electrophilic reactive species in inducing organ-directed toxicity is one of the most common causes for drug withdrawal (Park et al., 2006) . Mechanistically, these electrophilic species may bring about direct covalent modification of hepatic proteins to cause cellular dysfunction, or may form haptens, which in turn trigger an immune response, resulting in hepatotoxicity (Masubuchi and Horie, 2007) . Lapatinib has been shown to be a strong inhibitor of CYP3A4 (GlaxoSmithKine, 2007) . This information, coupled with its structural predisposition for metabolic activation and reactivity, led us to hypothesize that lapatinib undergoes biotransformation to form reactive electrophilic species that inhibit CYP3A4 irreversibly via mechanism-based inactivation.
CYP3A4 is the most abundant isoform of the CYP450 superfamily in humans. It has broad substrate specificity, and about 60% of xenobiotics are metabolized by CYP3A4. Mechanism-based inactivation of CYP3A4 may lead to accumulation of coadministered drugs in clinical practice, resulting in unforeseen toxicity (Lin et al., 2002) .
The number of drugs that have been characterized as mechanism-based inactivators (MBIs) has been increasing, due to our greater understanding of its clinical importance. MOL #65839 6 There are several criteria used in the characterization of MBIs, namely, time-dependency of inactivation; saturable kinetics of inactivation with respect to inhibitor concentration; inactivation in a catalytically competent system; substrate protection of enzyme from inactivation; lack of suppression of inactivation by exogenous nucleophiles; irreversibility of inactivation, and 1:1 binding stoichiometry of inactivator to inactivated enzyme (Rock et al., 2009) .
In this study, the nature of CYP3A4 inhibition by lapatinib was investigated based on the criteria in characterizing MBIs. GSH-trapping experiments were also performed to trace the formation of electrophilic reactive metabolites (RMs) of lapatinib that might contribute to any observed covalent modification of CYP3A4. Our results confirmed the generation of an electrophilic RM by lapatinib and established for the first time that lapatinib is a potent MBI of CYP3A4 most likely through oxidation of its O-dealkylated metabolite to a quinone imine.
MOL #65839 8 mixture in each well was 160 µl. The secondary incubation mixtures were further incubated for 10 min at 37°C before 50 µl aliquots were removed and quenched with an equal volume of ice-cold ACN and 0.008 µM verapamil (internal standard, IS). In the control incubations, 100 mM potassium phosphate buffer was used in place of NADPH.
The same experiment was repeated by replacing lapatinib with erythromycin (1-50 µM) and ketoconazole (0.05-10 µM), a known MBI and competitive inhibitor of CYP3A4, respectively. Samples were centrifuged for 16000 g at 4°C for 15 min and the supernatant was removed for determination of testosterone 6ß-hydroxylation activity by LC/MS/MS.
In a separate experiment, rCYP3A4 (20 pmol/ml) replaced HLM. Test compounds (50-500 µM) were incubated for up to 60 min in the primary incubation.
Time-, Concentration-, and NADPH-dependent CYP2C8 Inactivation.
Lapatinib (0.1 -10 µM), gemfibrozil glucuronide and quercetin (0.1-50 µM) were prepared in DMSO-acetonitrile (1:1, v/v) while amodiaquine was dissolved in Milli-Q water. The final acetonitrile and DMSO concentrations were less than 1% and 0.04% (v/v), respectively. To investigate the potential of lapatinib as a CYP2C8 MBI, the twostep incubation scheme described in the CYP3A4 assay was used. Gemfibrozil glucuronide is a known MBI of CYP2C8 while quercetin is a known competitive inhibitor. The probe substrate in the secondary incubation was 10 µM amodiaquine.
Partition Ratio. Primary incubations (n=3) comprising of 100 pmol/ml rCYP3A4, NADPH B, lapatinib (1, 1.5, 5, 10, 25, 50 and 75 µM) and 100 mM potassium phosphate buffer were prepared. After pre-incubation at 37°C for 6-8 min, the reaction was initiated by addition of NADPH A and the mixture was incubated at 37°C for another 45 min, allowing it to go to completion. The total volume in each well was 160
This article has not been copyedited and formatted. The final version may differ from this version. µl. 8 µl of the primary incubation was thereafter transferred to the secondary incubation mixture (similar to that prepared for the inactivation studies) and further incubated at 37°C. After 10 min, 50 µl aliquots were removed and quenched as described. In the negative control, the NADPH regenerating system was replaced with 100 mM potassium phosphate buffer in the primary incubation mixture. The samples were centrifuged for 16000 g at 4°C for 15 min and the supernatant was removed for determination of testosterone 6ß-hydroxylation activity by LC/MS/MS.
Effect of Exogenous Nucleophiles. 2 mM GSH was included in the primary incubation mixture (n=3) with 0.5 mg/ml HLM, 50 µM lapatinib, NADPH B and 100 mM potassium phosphate buffer. The reaction was initiated by addition of NADPH A after pre-incubation for 6-8 min at 37°C, to a final volume of 160 µl. 10 µl of aliquots were removed at 0, 4, 8, 15, 22, and 30 min and transferred to secondary incubation mixtures for measurement of residual CYP3A4 activity by LC/MS/MS. Negative controls were prepared by either excluding both GSH and lapatinib, or GSH only in the primary incubation mixture. Substrate Protection. Excess testosterone (in 1:8 and 1:16 molar ratios of lapatinib:testosterone) was added to the primary incubation mixture (n=3) containing 50 µM lapatinib, 100 pmol/ml rCYP3A4, NADPH B, and 100 mM potassium phosphate buffer. After pre-incubation for 6-8 min at 37°C, NADPH A was added to initiate the reaction. Aliquots were removed at 0, 3, 8, 15, 22, and 30 min and transferred to secondary incubation mixtures similar to that prepared in the time-dependent inhibition assay, and quantification of 6ß-hydroxytestosterone was determined using LC/MS/MS. This article has not been copyedited and formatted. The final version may differ from this version. Primary reaction mixtures that lacked either testosterone, or both lapatinib and testosterone were prepared as negative controls.
Spectral Difference Scanning. 200 pmol/ml rCYP3A4, NADPH regenerating system and 100 mM potassium phosphate buffer (pH 7.4) were pre-incubated at 37°C for 6-8 min. The reaction was initiated with the addition of 50 µM lapatinib. The sample mixture was immediately scanned from 400 to 500 nm, at 5 min intervals over a 60 min duration using an Infinite M200 Tecan microplate reader (Tecan Group Ltd, Männedorf, Switzerland) which was maintained at 37°C. The spectral differences were obtained by comparing between the sample and reference well (which contained the protein, substrate vehicle and NADPH). The positive control was prepared using 10 µM verapamil.
Reduced CO-difference spectroscopy. Incubations (n=3) were prepared using 50 µM lapatinib, NADPH B, 640 pmol/ml rCYP3A4 in 100 mM potassium phosphate buffer (pH 7.4). After pre-incubation at 37°C for 6-8 min, NADPH A was added to initiate the reaction. The total volume of this mixture was 50 µl and it was further incubated at 37°C. At 30 min, the reaction was terminated by the addition of 450 µl icecold quenching buffer which contained 1 mM EDTA, 20% glycerol, 1% Tergitol NP-40, 2 µM Safranin O and 100 mM potassium phosphate buffer (pH 7.4). The resultant mixture was split into two 250 µl tubes (sample and reference tubes). CO was bubbled into one of the tubes (sample tube) and stopped after approximately 60 bubbles had been passed into the mixture. About 1 mg of sodium dithionite was added to both tubes and 220 µl were transferred from each tube into a 96-well plate. The reduced CO-difference spectra for sample and reference wells were acquired by scanning from 400 to 500 nm This article has not been copyedited and formatted. The final version may differ from this version. using a microplate reader (Guengerich et al., 2009) . A negative control was prepared by excluding NADPH from the incubation mixture.
HLM Incubations For Identification of GSH Adducts. Incubation containing 1 mg/ml HLM, NADPH regenerating system, 100 mM potassium phosphate buffer (pH 7.4) and 50 mM GSH were preincubated at 37°C for 6-8 min. curtain gas (CUR) 20 psi, collision gas (CAD) medium, ionspray voltage (IS) 5500 V, temperature (TEM) 550°C, ion source gas 1 (GS1) 40 psi and ion source gas 2 (GS2) 45 psi. The compound-dependent MS parameters for 6ß-hydroxytestosterone were 6 V, 20 V, and 3 V for entrance potential (EP), collision energy (CE) and collision cell exit potential (CXP), respectively. For verapamil, the EP, CE and CXP were 7 V, 37 V and 2 V, respectively. The declustering potential (DP) and dwell for both 6ß-hydroxytestosterone and verapamil were 52 V and 250 ms, respectively.
Detection of GSH adducts. GSH adducts were analyzed using the same LC/MS/MS system as described above. Chromatographic separation was performed on an ACQUITY UPLC BEH C18 1.7 µm 100 × 2.1 mm i.d. column (Waters). Mobile phases were 0.1% formic acid (FA) in water (solvent A) and 0.1% FA in acetonitrile (solvent B) delivered at 0.45 ml/min. The elution conditions were: linear gradient 5-60% B (0-6.25 min), isocratic 95% B (6.26-7.09 min) and isocratic at 5% B (7.10-8.00 min).
The incubated samples were screened for GSH adducts in both electrospray ionization precursor mass set at m/z of the potential GSH adduct and centroid data were acquired for each sample from 100-900 Da with a 0.2 s scan time and a 0.02 s interscan delay. Prior to analysis, the system was calibrated in the ESI positive mode using a 0.5 M sodium formate solution infused at a flow rate of 5 μL/min. All analyses were acquired using an independent reference spray via the LockSpray™ interface to ensure high mass accuracy and reproducibility; the [M+H]+ ion of leucine enkephalin (2 ng/μL infused at 10 µL/min) was used as the reference lock mass (m/z 556.2771). The LockSpray™ was operated at a reference scan frequency, reference cone voltage and collision energy of 10 s, 30 V and 5 eV, respectively. Data Analysis. All chromatographic peak integration was performed using Analyst 1.4.2. To determine the time-, concentration-, and NADPH-dependent activity in the mechanism-based inactivation assays, the mean of triplicate analyses was used to calculate the natural log of percentage probe substrate activity remaining normalized to 0 min against pre-incubation time. The data were fitted to linear regression and the observed first-order inactivation rate constant, K obs , was determined. Kinetic parameters, K i and K inact , were determined by a Kitz-Wilson plot (Kitz and Wilson, 1962) to reflect the degree of inactivation of the specific CYP enzyme. These plots were acquired using GraphPad Prism 4.0 (San Diego, CA, USA). Firstly, we investigated the possible involvement of mechanism-based inactivation of CYP3A4 by lapatinib in preincubations with or without NADPH. Testosterone was used as the substrate and the formation of testosterone-6β-hydroxylation was used to measure the enzyme activity. Fig. 2A shows that lapatinib inhibited CYP3A4 in a NADPHdependent manner. The absence of NADPH in HLM incubations did not show any significant decline in CYP3A4 activity when incubated with lapatinib over the preincubation time of 30 min. On the other hand, the presence of NADPH showed a more pronounced concentration-and time-dependent decrease in CYP3A4 activity. This trend was corroborated with lapatinib in rCYP3A4 incubations for up to 60 min (data not shown).
When HLM were pre-incubated with lapatinib in the presence of NADPH for up to 30 min, testosterone-6β-hydroxylation activity declined in a time-and concentrationdependent manner (Fig. 2B) . Erythromycin, a known MBI of CYP3A4, and lapatinib demonstrated time-dependent decrease of activity with both HLM and rCYP3A4. On the other hand, the negative control, ketoconazole (a potent competitive CYP3A4 inhibitor), did not show any pre-incubation time-dependent decrease in activity. Similar to erythromycin, lapatinib caused a loss in testosterone hydroxylase activity that followed pseudo-first order kinetics. The kinetic parameters were determined from a Kitz-Wilson plot (Fig 2B, inset) . Previously, lapatinib was reported as a mixed-competitive inhibitor . Lapatinib and the controls exhibited both timeand concentration-dependent decreases in activity with HLM. However, CYP2C8 inhibition was not increased when HLM were pre-incubated with quercetin and lapatinib in the presence of NADPH. Conversely, a significant decrease in CYP2C8 activity was observed when gemfibrozil glucuronide was pre-incubated with HLM plus a NADPHregenerating system. Hence, our observations suggested that lapatinib is not a MBI of CYP2C8.
Partition Ratio. A titration method (Silverman, 1995) was used to determine the partition ratio, which is the number of inactivator molecules metabolized per molecule of enzyme inactivated. Metabolism of lapatinib using rCYP3A4 was performed to completion and 6ß-hydroxytestosterone was used to measure residual CYP3A4 activity.
Lapatinib was incubated with rCYP3A4 in the presence of NADPH for 45 min until the reaction was completed. line at lower ratios and the straight line for the higher ratios to the x-axis gave a turnover number of 51.9. Subtracting one from this value yielded a partition ratio of 50.9.
Effect of Exogenous Nucleophiles and Alternate Substrate on Inactivation.
Addition of GSH (exogenous nucleophile) did not affect the rate of enzyme inactivation.
As shown in Fig. 3B , CYP3A4 was inactivated to a similar extent as compared to that during incubation with lapatinib alone. Co-incubation with 8-and 16-fold excess of testosterone, an alternate substrate of CYP3A4, protected the enzyme from inactivation by lapatinib, as seen in the diminished rate of inactivation with time (Fig. 3C) .
Spectral Difference Scanning. MIC-forming compounds tend to show a characteristic peak in the Soret region (448-458 nm) (Polasek and Miners, 2008) . When spectral differences were obtained by scanning from 400 to 500 nm for 60 min, lapatinib did not show any observable peak in the Soret region when incubated with CYP3A4 ( Fig.   3D ) while verapamil (a known MIC of CYP3A4) produced a clear peak at 448-458 nm (supplementary data, Fig. 2 ).
Reduced CO-difference spectroscopy. Ferrous (reduced) cytochrome P450 forms a complex with CO to give a spectrally detectable peak at 450 nm. Using the formula for calculating CYP450 concentration ([ΔA450-ΔA490]/0.091=nmol of P450 per ml) (Guengerich et al., 2009) , the extent of reduction in the 450 nm peak was derived.
When 50 µM lapatinib was incubated with CYP3A4 for 30 min, there was a 43 ± 7.8% decrease in the peak at 450 nm (n=3) as compared to the control incubation in the absence of NADPH. incubations. Pre-screening of GSH-adducts with metabolites of lapatinib were conducted over five separate m/z ranges from m/z 400 to 900 to ensure optimal MS sensitivity. One peak with m/z 778 (LAPA-G1; R.T. 2.03 min) suggestive of a GSH adduct was observed in the precursor scan at m/z 272 in the ESI negative mode and was not observed in any of the negative controls (Fig. 4A) . Co-incubation with ketoconazole resulted in reduction of the peak (Fig. 4B) . The GSH-trapping assay was repeated by incubating O-dealkylated lapatinib in HLM and both LAPA-G1 and LAPA-G2 were also observed in the LC/MS/MS analysis (Fig. 4C) .
The EPI scans of LAPA-G1 (Fig. 5A ) generated a spectrum characteristic of collision-induced dissociation fragmentation of GSH where there was a neutral mass loss of 129 corresponding to loss of the pyroglutamic acid moiety. Neutral loss scan at m/z 123 was further performed to profile any additional GSH adducts that shared a similar fragmentation pattern to LAPA and a peak at 1.83 min (m/z 649) was detected (Fig. 4 and 5B). To further confirm the identity of the potential GSH adduct, accurate mass measurements were performed using QTOFMS. The program MassLynx was used to determine the potential calculated masses, mass accuracy (mDa and ppm), i-FIT (Norm) (the likelihood that the isotopic pattern of the elemental composition matches a cluster of peaks in the spectrum) values and elemental compositions associated with the measured mass of the GSH adducts and their fragments were generated and summarized in Table 1 . 
DISCUSSION
Mechanism-based inactivation of P450 enzymes is preceded by formation of a reactive intermediate, and therefore requires NADPH and exhibits both time-and concentration-dependence (Ito et al., 1998) . Lapatinib was found to inhibit CYP3A4 in accordance with these criteria with reproducible K i and k inact values, using a catalytically competent system. We attested the reliability of our data by measuring the K i and k inact values of the classic CYP3A4 MBI, erythromycin, and found values consistent with those in the published literature (Table 2) . Notably, the k inact /K i ratio for lapatinib was lower than that observed for troleandomycin, but higher than clinically relevant MBIs such as erythromycin, dihydralazine and clarithromycin. Erythromycin can cause Torsades de pointes when co-administered with terfenadine, cisapride or astemizole, and rhabdomyolysis with simvastastin (Spinler et al., 1995) through DDIs. Likewise, dihydralazine had been reported to induce immunoallergic hepatitis (Masubuchi and Horie, 1999) . Therefore, it is reasonable to postulate that lapatinib, being an even more potent MBI, may be capable of inducing hepatotoxicity through DDI and/or immunemediated toxicity (Uetrecht, 2007) . However, additional clinical data and development of an animal model will be required to determine the exact mechanism of lapatinibmediated hepatotoxicity.
A MBI's efficiency is estimated by its partition ratio, which is the number of times each CYP450 turns over the drug before a reactive intermediate inactivates the enzyme. The measured partition ratio for lapatinib was 50.9, a relatively high value compared to those reported for numerous CYP3A4 MBIs (Ghanbari et al., 2006) . Coincubation with GSH did not affect the rate of CYP3A4 inactivation by lapatinib, which The absence of a Soret peak ruled out the possibility of pseudo-irreversible MIC formation by lapatinib, which suggests that CYP3A4 was irreversibly inactivated by a lapatinib metabolite, most likely via covalent modification of the enzyme. This possibility was supported by reduced CO-difference spectroscopy which showed a 43% loss of spectrally detectable CYP3A4-CO complex at 450 nm in the presence of lapatinib accompanied by an increase in absorption at 420 nm. While reduction in absorption at 450 nm could be linked to either heme adduction or heme destruction, covalent adduction of a RM to apo-protein in close proximity to the heme moiety could compromise the integrity of the CYP3A4 active site. This could, thereby, interfere with CO-heme binding and lead to an increase in absorption at 420 nm (Omura T and Sato R, 1964) . Covalent adduction to apo-protein has been demonstrated for MBIs such as bergamottin (He et al., 1998) and mifepristone (He et al., 1999) , while the MBI formed from 17-ethynylestradiol forms adducts to both heme and apo-protein (Lin et al., 2002) . Although further work is required to determine how lapatinib inhibits CYP3A4 at the molecular level, we hypothesize that the quinoneimine of the O-dealkylated metabolite of lapatinib binds to the apoprotein of CYP3A4, since it is a relatively soft electrophile that would react with soft nucleophiles on proteins.
The para-aminophenol group of the O-dealkylated metabolite of lapatinib (M1, Fig. 1 ) provided an initial structural alert to its potential toxicity mechanism since it could be oxidized to the reactive quinoneimine species, based on parallels of studies with Nacetyl-p-benzo-quinoneimine generated from the cytochrome P450 oxidation of acetaminophen (Dahlin et al., 1984; Albano et al., 1985) . Moreover, it was confirmed that lapatinib did not inhibit CYP2C8 as a MBI, although it is a competitive inhibitor for this enzyme, which suggests that lapatinib may be metabolized differently or to a different extent by CYP3A4 as compared to CYP2C8. A RM-GSH adduct, LAPA-G1, was identified in the present study, (Fig. 4) . The accurate mass-to-charge (m/z) ratios of the parent and product ions of LAPA-G1 fell within 5 ppm (Table 1A ). Coupled to the strong i-FIT values (< 5 units) that indicated good fit with the isotopic pattern of each ion, our confidence in the assignment of elemental compositions of the parent and product ions was significantly enhanced. The RM was a quinoneimine generated from the oxidation of the para-aminophenol group of the O-dealkylated metabolite (LAPA-G1; m/z 778; Fig. 5A ). This was further confirmed by the detection of LAPA-G1 in the incubated sample of O-dealkylated lapatinib with HLM and GSH (Fig 4C) . The proposed bioactivation pathway of lapatinib is summarized in Fig. 6 . This bioactivation parallels that of other structurally similar tyrosine kinase inhibitors such as dasatinib (Li et al., 2009) (Fig. 4B) , confirming that the RM was generated from oxidative metabolism by CYP3A4.
Interestingly, another adduct, LAPA-G2 (m/z 649), was observed and confirmed to be metabolically-derived (Fig. 4) . Its fragmentation pattern lacked the characteristic neutral loss of 129 associated with a typical RM-GSH adduct (Fig. 5B) . It was also noted that the mass difference between LAPA-G1 and G2 was 129, corresponding to the loss of the pyroglutamic acid moiety of GSH. Furthermore, LAPA-G2 demonstrated fragmentation losses of 123 and a fragment ion at m/z 382, of all which are characteristic of the fragmentation pattern of lapatinib. The accurate mass-to-charge (m/z) ratios of the parent and product ions of LAPA-G2 are within 5 ppm (Table 1B) and low i-FIT values (< 3 units). These collectively suggested that LAPA-G2 was a cysteinylglycine conjugate, the secondary metabolite of LAPA-G1 derived from the mercapturate pathway as catalyzed by γ-glutamyltransferase (GGT), a human liver microsomal enzyme (Fig. 6) .
In GSH conjugation of xenobiotics, the mercapturate pathway is a common detoxification route (Stevens, 1989) .
Our results raise the possibility that lapatinib-related hepatotoxicity may be an idiosyncratic drug reaction (IDR) which occurs at continuous high dosing. This is in agreement with reports of C max and AUC increases that are more than dose-proportional , 1997) . It was observed that drugs administered at less than 10 mg/day are generally rarely associated with IDRs (Uetrecht, 1999) while drugs dosed more than 1 g/day (e.g. felbamate) are more likely to cause IDRs (Uetrecht, 2007) .
Hence, the 1.25 g/day dosing for lapatinib (European Medicines Agency, 2008) could reasonably exceed the threshold level for toxicity in a susceptible subpopulation.
Therefore, any involvement of immuno-hepatotoxicity with lapatinib could not be excluded. In fact, the high therapeutic dose of lapatinib, coupled to its efficiency as a CYP3A4 MBI, could presumably trigger protein modification and immune response, such as with tienilic acid, which caused rare idiosyncratic hepatotoxicity upon mechanism-based inactivation of CYP2C9, resulting in antibodies formation against CYP2C9 (Masubuchi and Horie, 2007) . Nevertheless, although IDRs appear to be RMdriven and immune-mediated, host genetic and environmental influences can also be contributory (Uetrecht, 2007) . Hence, the clinical characteristics of lapatinib-related hepatotoxicity are crucial in understanding the toxicity mechanism.
In conclusion, we demonstrated for the first time that lapatinib is a CYP3A4 MBI via covalent modification of its apoprotein and/or heme moiety, and elucidated the structure of the RM possibly involved in the irreversible inactivation of the enzyme. 
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